|
[1]XU KC.Investigation of treatment strategy for advanced cancer according to treatment of pancreatic cancer[J].J Clin Hepatol, 2013, 29 (7) :484-488. (in Chinese) 徐克成.从胰腺癌治疗探讨进展期癌症治疗策略[J].临床肝胆病杂志, 2013, 29 (7) :484-488.
|
|
[2] JEMAL A, SIEGEL R, XU J, et al.Cancer statistics, 2010[J].CA Cancer J Clin, 2010, 60 (5) :277-300.
|
|
[3]LEUNG DW, CACHIANES G, KUANG WJ, et al.Vascular endothelial growth factor is a secreted angiogenic mitogen[J].Science, 1989, 246 (4935) :1306-1309.
|
|
[4]ZORGETTO VA, SILVEIRA GG, OLIVEIRA-COSTA JP, et al.The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A) expression with clinicalpathological features and survival in pancreaticadenocarcinomas[J].Diagn Pathol, 2013, 8:170.
|
|
[5]WEIDNER N.Tumoral vasculary as a prognostic factor in cancer patients:the evendence continues to grow[J].J Pathol, 1998, 184 (2) :119-122.
|
|
[6]ROGERS A, SMITH MJ, DOOLAN P, et al.Invasive markers identified by gene expression profiling in pancreatic cancer[J].Pancreatology, 2012, 12 (2) :130-140.
|
|
[7]HILDENBRAND R, NIEDERGETHMANN M, MARX A, et al.Amplification of theurokinasetype plasm inogen activator receptor (uPAR) gene in ductal pancreatic carcinomas identifies a clinically highrisk group[J].Am J Pathol, 2009, 174 (6) :2246-2253.
|
|
[8]DOBRILA-DINTINJANA R, VANIS N, DINTINJANA M, et al.Etiology and oncogenesis of pancreatic carcinoma[J].Coll Antropol, 2012, 36 (3) :1063-1067.
|
|
[9]ASUTHKAR S, STEPANOVA V, LEBEDEVA T, et al.Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer[J].Mol Biol Cell, 2013, 24 (17) :2620-2632.
|
|
[10]SCHLAEPI JM, WOOD JM.Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors[J].Cancer Metastasis Res, 1999, 18 (4) :473-481.
|
|
[11]NIETHAMMER AG, LUBENAU H, MIKUS G, et al.Doubleblind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGFReceptor 2 in patients with stage IV and locally advanced pancreatic cancer[J].BMC Cancer, 2012, 12:361.
|
|
[12]HBEL S, KOBURGER I, JOHN M, et al.Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab[J].J Gene Med, 2010, 12 (3) :287-300.
|
|
[13]MARTIN LK, LI X, KLEIBER B, et al.VEGF remains an interesting target in advanced pancres cancer (APCA) :results of a multi-institutional phase II study of bevacizumab, gemicitabine, and infusional 5-fluorouracil in patients with APCA[J].Ann Oncol, 2012, 23 (11) :2812-2820.
|
|
[14]HILEY CT, CHARD LS, GANGESWARAN R, et al.Vascular endothelial growth factor A promotes vaccinia virus entry into host cells via activation of the Akt pathway[J].J Virol, 2013, 87 (5) :2781-2790.
|
|
[15]KINDLER HL, NIEDZWIECKI D, HOLLIS D, et al.Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phaseⅢtrial of the Cancer and Leukemia Group B (CALGB 80303) [J].J Clin Oncol, 2010, 28 (22) :3617-3622.
|
|
[16]VAN CUTSEM E, VERVENNE WL, BENNOUNA J, et al.PhaseⅢtrial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer[J].J Clin Oncol, 2009, 27 (13) :2231-2237.
|
|
[17]LU JD.Novel therapeutic strategies for advanced pancreatic cancer:targeting the epidermal growth factor and vascular endothelial growth factor pathways[J].China Oncol, 2009, 19 (8) :590-596. (in Chinese) 陆嘉德.晚期胰腺癌的分子靶向治疗[J].中国癌症杂志, 2009, 19 (8) :590-596.
|
DownLoad: